Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis.
The aim of this study was to assess the structural efficacies of daily glucosamine sulfate and chondroitin sulfate in patients with knee osteoarthritis (OA). The authors surveyed randomized controlled studies that examined the effects of long-term daily glucosamine sulfate and chondroitin sulfate on joint space narrowing (JSN) in knee OA patients using the Medline and the Cochrane Controlled Trials Register, and by performing manual searches. Meta-analysis was performed using a fixed effect model because no between-study heterogeneity was evident. Six studies involving 1,502 cases were included in this meta-analysis, which consisted of two studies on glucosamine sulfate and four studies on chondroitin sulfate. Glucosamine sulfate did not show a significant effect versus controls on minimum JSN over the first year of treatment (SMD 0.078, 95% CI -0.116 to -0.273, P = 0.429). However, after 3 years of treatment, glucosamine sulfate revealed a small to moderate protective effect on minimum JSN (SMD 0.432, 95% CI 0.235-0.628, P < 0.001). The same was observed for chondroitin sulfate, which had a small but significant protective effect on minimum JSN after 2 years (SMD 0.261, 95% CI 0.131-0.392, P < 0.001). This meta-analysis of available data shows that glucosamine and chondroitin sulfate may delay radiological progression of OA of the knee after daily administration for over 2 or 3 years.
Lee
Young Ho
YH
Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 126-1 ga, Anam-dong, Seongbuk-gu, Seoul 136-705, Korea. lyhcgh@korea.ac.kr
Woo
Jin-Hyun
JH
Choi
Seong Jae
SJ
Ji
Jong Dae
JD
Song
Gwan Gyu
GG
D002809:Chondroitin Sulfates / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D004334:Drug Administration Schedule; D005944:Glucosamine / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007719:Knee Joint / Q000187:drug effects / Q000503:physiopathology; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology; D017063:Outcome Assessment, Health Care; D012042:Registries; D016896:Treatment Outcome
D002809:Chondroitin Sulfates; D005944:Glucosamine